The LARS® ACJ system, constructed from biocompatible polyethylene terephthalate, functions as a knitted surgical scaffold to support fixation during the healing of acromioclavicular separations. While this initial clearance focuses on shoulder joint repair, it serves as a gateway for the company to introduce its broader portfolio of synthetic ligament technologies to American surgeons. Movmedix currently supports 11 clinical indications globally, with its implants utilized in more than 250,000 patient procedures.
In section Releases
French MedTech Firm Movmedix Enters U.S. Market with FDA Approval
After three decades of European clinical use, the French orthopedic firm Movmedix has secured its first U.S. Food and Drug Administration 510(k) clearance. The approval authorizes the commercial launch of the company’s LARS® ACJ system, a synthetic implant designed to stabilize shoulder injuries caused by ligament trauma.
French Engineering Meets U.S. Clinical Demand
Ligament injuries remain a significant public health burden, particularly among athletes and military personnel. With over 200,000 ACL injuries reported annually in the United States, the demand for reliable reconstruction solutions is high. CEO Hervé Legrand noted that the FDA milestone validates the company’s long-term investment in clinical science and manufacturing. Headquartered near Dijon, the firm has expanded its footprint to 36 countries, leveraging its proprietary free-fiber technology to gain market share. Following the regulatory green light, Movmedix plans to debut its U.S. operations at the 2026 AOSSM Annual Meeting in Seattle, marking the start of a phased commercial rollout and a multi-product regulatory roadmap.
Comments (0)
No comments yet. Be the first!